Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe.

about

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe.

Item

http://www.wikidata.org/entity/Q55317277

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@en

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@nl

type

Item

label

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@en

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@nl

prefLabel

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@en

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@nl

P1476

Managed Entry Agreements for P ...... f Adaptive Pathways in Europe.

@en

P2093

Claudine Sapede

http://www.w3.org/2001/XMLSchema#string

Jacoline C Bouvy

http://www.w3.org/2001/XMLSchema#string

Sarah Garner

http://www.w3.org/2001/XMLSchema#string

P2860

A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

What principles should govern the use of managed entry agreements?

Adaptive licensing: taking the next step in the evolution of drug approval.

Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.

P304

280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2018.00280

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29636692

http://www.w3.org/2001/XMLSchema#string

P932

5881456

http://www.w3.org/2001/XMLSchema#string